Momentum in festive season launches the key factor to watch
To focus on molecules at advanced stage of development; move to impact 200 scientists
Container volumes, expansion initiatives will help the company post better earnings growth
With revenues from diabetes and cardiovascular portfolio at risk, analysts remain cautious
Higher domestic demand, increasing exports and localisation should aid revenues, margins
Losses have come down but it might take a couple of quarters before revenues stabilise, given the senior management exits at corporate and editorial levels
Pricing restrictions on top products have dented sales growth, which will take a few quarters to revive
Market players believe unless the stake sale is done before Diwali, the govt may find it hard to get a good valuation
Information technology and pharma continue to remain outliers
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15
US will continue to be a key growth driver with new launches as well product portfolio helping it to achieve guidance of 15% revenue growth for FY5
Given the launch of compact UVs will be next year, recovery in market share is a some quarters away
Given the run-up in stock prices of both firms, there might not be major gains from current levels
While commercial vehicle recovery in India is the trigger, analysts say margins close to peaking
Remains confident of sustaining volume growth on new launches; festival period might boost sales
However, FII holding in most good quality large cap companies is close to peak levels
Fall in revenues in the June quarter was due to lack of new launches, weak demand and lower realisations
Honda Mobilio and Tata Zest could challenge one-third of Maruti's earnings
Given rich valuations, upside for the stock capped for now